Safety and tolerability of single low-dose primaquine in a low-intensity transmission area in South Africa: an open-label, randomized controlled trial

Malaria Journal

  ^{1    2    3    4    5    5    5    6    7} 

[1] 0000 0001 2107 2298, grid.49697.35, UP Institute for Sustainable Malaria Control and MRC Collaborating Centre for Malaria Research, University of Pretoria, Pretoria, South Africa;0000 0004 0630 4574, grid.416657.7, Parasitology Reference Laboratory, National Institute for Communicable Diseases, A Division of the National Health Laboratory Services, Johannesburg, South Africa;0000 0004 1937 1135, grid.11951.3d, Wits Research Institute for Malaria, Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa;0000 0004 0630 4574, grid.416657.7, Parasitology Reference Laboratory, National Institute for Communicable Diseases, A Division of the National Health Laboratory Services, Johannesburg, South Africa;0000 0004 1937 1135, grid.11951.3d, Wits Research Institute for Malaria, Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa;0000 0004 1937 1151, grid.7836.a, UCT/MRC Collaborating Centre for Optimising Antimalarial Therapy, University of Cape Town, Cape Town, South Africa;0000 0004 1937 1151, grid.7836.a, Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa;0000 0004 1937 1151, grid.7836.a, UCT/MRC Collaborating Centre for Optimising Antimalarial Therapy, University of Cape Town, Cape Town, South Africa;0000 0004 1937 1151, grid.7836.a, Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa;0000 0004 1937 1151, grid.7836.a, UCT/MRC Collaborating Centre for Optimising Antimalarial Therapy, University of Cape Town, Cape Town, South Africa;0000 0004 1937 1151, grid.7836.a, Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa;Mpumalanga Provincial Malaria Elimination Programme, Mpumalanga, South Africa;Mpumalanga Provincial Malaria Elimination Programme, Mpumalanga, South Africa;

关键词: Primaquine;    Artemether–lumefantrine;    Efficacy;    Safety;    Tolerability;    Gametocyte carriage;    South Africa;    Plasmodium falciparum;   

DOI  :  10.1186/s12936-019-2841-8

来源: publisher

【 摘 要 】

BackgroundTo reduce onward falciparum malaria transmission, the World Health Organization recommends adding single low-dose (SLD) primaquine to artemisinin-based combination treatment in low transmission areas. However, uptake of this recommendation has been relatively slow given concerns about whether individual risks justify potential community benefit. This study was undertaken to generate comprehensive local data on the risk–benefit profile of SLD primaquine deployment in a pre-elimination area in South Africa.MethodsThis randomized, controlled open-label trial investigated adding a single low primaquine dose on day 3 to standard artemether–lumefantrine treatment for uncomplicated falciparum malaria. Efficacy, safety and tolerability of artemether–lumefantrine and primaquine treatment were assessed on days 3, 7, 14, 28 and 42. Lumefantrine concentrations were assayed from dried blood spot samples collected on day 7.ResultsOf 217 patients screened, 166 were enrolled with 140 randomized on day 3, 70 to each study arm (primaquine and no primaquine). No gametocytes were detected by either microscopy or PCR in any of the follow-up samples collected after randomization on day 3, precluding assessment of primaquine efficacy. Prevalence of the CYP2D6*4, CYP2D6*10 and CYP2D6*17 mutant alleles was low with allelic frequencies of 0.02, 0.11 and 0.16, respectively; none had the CYP2D6*4/*4 variant associated with null activity. Among 172 RDT-positive patients G6PD-genotyped, 24 (14%) carried the G6PD deficient (A−) variant. Median haemoglobin concentrations were similar between treatment arms throughout follow-up. A third of participants had a haemoglobin drop > 2 g/dL; this was not associated with primaquine treatment but may be associated with G6PD genotype [52.9% (9/17) with A− genotype vs. 31% (36/116) with other genotypes (p = 0.075)]. Day 7 lumefantrine concentrations and the number and nature of adverse events were similar between study arms; only one serious adverse event occurred (renal impairment in the no primaquine arm). The artemether–lumefantrine PCR-corrected adequate clinical and parasitological response rate was 100%, with only one re-infection found among the 128 patients who completed 42-day follow-up.ConclusionsSafety, tolerability, CYP2D6 and G6PD variant data from this study support the deployment of the WHO-recommended SLD primaquine without G6PD testing to advance malaria elimination in South African districts with low-intensity residual transmission.Trial registration Pan African Clinical Trial Registry, PACTR201611001859416. Registered 11 November 2016, https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=1859

【 授权许可】

CC BY